Atomrobot filed for HKEX IPO with Huatai. Leading high-speed parallel robot maker, ranking first in China for five consecutive years per Frost & Sullivan.
InSilico Medicine has partnered with Qilu Pharmaceutical in a deal worth over HK$931 million to develop small molecule inhibitors for cardiovascular and metabolic diseases using its Pharma.AI platform, with milestone payments and single-digit sales royalties.
NewTimeSpace News: SSY Group Limited (02005.HK) released a voluntary announcement on the 26th stating that it has obtained the drug production registration approval from the National Medical Products Administration of China (NMPA) for the new 2ml specification of Potassium Dihydrogen Phosphate Complex Injection. Classified as a Class 3 chemical drug, the product is deemed to have passed the consistency evaluation.
NewTimeSpace News, HENGRUI PHARMA announced on January 26 that it has received the "Drug Clinical Trial Approval Notice" for SHR-1049 Injection issued by the National Medical Products Administration (NMPA), which grants approval for the drug to conduct a single-agent clinical trial for the treatment of advanced solid tumors.
IPLUSMOBOT Technology filed for HKEX IPO on Jan 23, 2026, ranking among the global top 5 industrial intelligent mobile robot players by order value. The company posted 2024 revenue of RMB 115 million (+53.2% YoY) and RMB 201 million for 9M 2025, with improving margins but ongoing losses. Backed by ByteDance and Lenovo, it targets R&D and global expansion with the proceeds.
ASIAINFO TECH disclosed in an announcement on January 26 that it has jointly established the "Embodied Intelligence Lab" with ABB Robotics, with technical support from Alibaba Cloud and NVIDIA. This marks the substantial implementation stage of the strategic cooperation between the two parties in the field of Physical AI (Physical Artificial Intelligence).
Guoyi Medical Technology has formally submitted an application for a Main Board listing on the Hong Kong Stock Exchange. As the leader of China's third-party SPD solution market, the company held a 29.2% market share in 2024. Financial data shows that its net profit surged 368% year-on-year to RMB 57.585 million in 2024. The company's business covers 116 hospitals across 13 provinces in China, with shareholders including iFlytek Venture Capital and Xinli Capital.
TIANGONG INT'L announced on January 16 that its subsidiary Tiangong Aihe has been approved to join the Fusion High-End Metal Materials R&D Joint Laboratory led by the Energy Research Institute of Hefei Comprehensive National Science Center, with a five-year validity period of the agreement. Tiangong Aihe will focus on two core R&D tasks, helping the Group explore downstream application areas of nuclear fusion and enrich its powder metallurgy business.
XTX Technology recently submitted its listing application to the Hong Kong Stock Exchange. According to CIC, by 2024 revenue, the company ranked sixth among global code-type flash memory chip fabless companies with a 3.7% market share. The prospectus shows that the company's revenue was RMB 442 million with a net loss of RMB 37.136 million in 2024, but achieved a profit turnaround in the first nine months of 2025.
CES 2026 takeaway: memory-rich end-to-end agents will replace toolkits within 24 mos; charge early—AI inference cost kills freemium.
Unique Research's CES 2026 closed-door dialogue reveals AI companies must abandon internet-era thinking and adopt "tiered subscription + usage limits" hybrid models. Tanka CEO Kisson Lin and Emmy-nominated producer Jesse Z analyze market selection, localization, fundraising, and pricing strategies, declaring the freemium model dead. AI firms should charge early to validate value, with future AI evolving into autonomous Agents with enhanced memory and contextual capabilities.
Biocytogen (2315) announced on January 12 an option and license agreement with Acepodia, granting global exclusive options on two BsADC projects to accelerate bispecific antibody-dual drug conjugate (BsAD2C) development. Biocytogen will receive upfront and subsequent milestone payments plus royalties. The collaboration combines Biocytogen's RenLite® platform with Acepodia's AD2C technology, building upon a joint development partnership initiated earlier this year. Acepodia and its ultimate beneficial owners are independent of Biocytogen and its connected persons, and the transaction does not constitute a connected transaction. The company cautions shareholders and potential investors to exercise prudence when trading its shares.
Brain-computer interfaces became a market hotspot in early 2026, primarily driven by news that Neuralink—under Elon Musk—plans to mass-produce devices in 2026. According to public information, Neuralink has completed multiple human implantations, with its invasive technology path aimed at treating neurological diseases. Kaiyuan Securities analysis points out that the industry is still in the early stages of commercialization, with the market characterized by thematic investment style.
Peking University Resources (Holdings) Company Limited (00618.HK) announced that ResoHealth, the Group’s Dubai-based healthcare business unit, has partnered with Trivitron Healthcare to launch the Trivitron Digital AI Digital Health Initiative in India. The platform aims to enhance the operational efficiency of hospitals and the patient diagnosis and treatment experience in India’s tier-2 and tier-3 cities through cloud solutions and AI technologies, with future plans to expand into the African, Middle Eastern and Southeast Asian markets.
MIRXES-B (02629.HK) announced that it has established a strategic cooperation with N Health, an affiliate of BDMS (Bangkok Dusit Medical Services (BDMS) Group)—Thailand’s largest healthcare provider—to jointly promote miRNA cancer screening solutions in Thailand. In addition, two of the Company’s at-home test kits (Helicobacter pylori and fecal occult blood tests) have obtained approval from Thailand’s FDA and are officially launched on January 9, 2026.
Galaxis Technology has re-submitted its listing application to the Hong Kong Exchanges and Clearing Limited (HKEX) in recent days. According to data from Frost & Sullivan, based on shipment volume in 2024, the company is the largest supplier in China's Very Narrow Aisle Autonomous Mobile Robot (VNA AMR) sector, with a market share of 19.3%. The prospectus shows that the company recorded an operating revenue of RMB 721 million in 2024, yet it has not achieved profitability during the reporting period, with a significant cumulative loss.
